ConductScience.org, home

Trial · NCT05288504

Outcomes13

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured as
PRIMARYThe Ability of AVTX-002 to Improve Asthma Control in Subjects With Poorly Controlled Non-eosinophilic Asthma (NEA) Based on the Percentage of Patients Who Experience Asthma Related Events.Through Week 14Full Analysis SetParticipantsCOUNT_OF_PARTICIPANTS
SECONDARYChange From Baseline to Week 14 in Forced Expiratory Volume in 1 Second (FEV1[Liters]).Through Week 14Full Analysis Set with all subjects with baseline and Week 14 data available.LiterMEAN
SECONDARYTime to Asthma Exacerbation.Through Week 14Full Analysis SetdaysMEAN
SECONDARYChange From Baseline to Week 14 in Fractional Exhaled Nitric Oxide (FeNO).Through Week 14Full Analysis Set with all subjects with baseline and Week 14 data available.Parts per billionMEAN
SECONDARYChange From Baseline to Week 14 in Asthma Control Questionnaire (ACQ).Through Week 14Full Analysis Set with all subjects with baseline and Week 14 data available.score on a scaleMEAN
SECONDARYChange From Baseline to Week 14 in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12).Through Week 14Full Analysis Set with all subjects with baseline and Week 14 data available.score on a scaleMEAN
SECONDARYChange From Baseline to Week 14 in Asthma Symptom Diary Score.Through Week 14Full Analysis Set with all subjects with baseline and Week 14 data available.units on a scaleMEAN
SECONDARYChange From Baseline to Week 14 in European Quality of Life - 5 Dimension 5 Level Questionnaire in Visual Analogue Scale Score (EQ VAS).Through Week 14Full Analysis Set with all subjects with baseline and Week 14 data available.units on a scaleMEAN
SECONDARYChange From Baseline to Week 14 in Patient Global Impression of Change/Severity.Through Week 14Full Analysis Set with all subjects with baseline and Week 14 data available.units on a scaleMEAN
SECONDARYChange From Baseline to Week 14 in Clinician Global Impression of Improvement/Severity.Through Week 14Full Analysis Set with all subjects with baseline and Week 14 data available.units on a scaleMEAN
SECONDARYThe Number of Inhalations of Short-acting Beta Agonist (SABA) at Week 14.Through Week 14Full Analysis Set with all subjects with baseline and Week 14 data available.number of inhalationsMEAN
SECONDARY
Change From Baseline to Week 14 in Serum Soluble LIGHT Levels (Lymphotoxin-like, Exhibits Inducible Expression, and Competes With Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator, a Receptor Expressed by T Lymphocytes).
Through Week 14Full Analysis Set with all subjects with baseline and Week 14 data available.pg/mLMEAN
SECONDARYIncidence of Anti-drug Antibodies (ADAs) at Each Timepoint.Baseline, Week 2, Week 4, Week 6, Week 8, Week 12 and Week 14.Safety Analysis Set: Data only collected for AVTX-002 Arm/Group.ParticipantsCOUNT_OF_PARTICIPANTS

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05288504/outcomes